Neuphoria Therapeutics is headquartered at 100 Summit Dr, Burlington, MA 01803
Neuphoria was incorporated in 2024 in the state of Delaware.
Neuphoria Therapeutics is traded on the NASDAQ Global Market under the ticker symbol NEUP and its CUSIP number is 64136E102.
Neuphoria Therapeutics’ went public on December 24, 2024.
Neuphoria Therapeutics’ fiscal year end is June 31st.
Neuphoria Therapeutics does not have a direct stock purchase plan. Shares can be purchased through a stockbroker of your choice.
Neuphoria Therapeutics’ independent auditors are Wolf & Company, P.C.
The Neuphoria Therapeutics press release archives can be accessed via the news releases page.
Alerts can be set up from the “Email Alerts” section of the “Investors” page.
The Neuphoria Therapeutics SEC filings can be accessed from the “SEC Filings” section of the “Investors” page or www.sec.gov.
For further questions please send us an email at ir@neuphoriatx.com